<SEC-DOCUMENT>0001193125-11-288630.txt : 20111031
<SEC-HEADER>0001193125-11-288630.hdr.sgml : 20111031
<ACCEPTANCE-DATETIME>20111031155154
ACCESSION NUMBER:		0001193125-11-288630
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111025
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111031
DATE AS OF CHANGE:		20111031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27436
		FILM NUMBER:		111168259

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		4152444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d251175d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE
COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of&nbsp;the </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): October&nbsp;25, 2011 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Titan
Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of incorporation) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-27436</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-3171940</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>

<TR>
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>400 Oyster Point Blvd., Suite 505,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>South San Francisco, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94080</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: 650-244-4990 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, is Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
October&nbsp;26, 2011, Titan Pharmaceuticals, Inc. (the &#147;Company&#148;) issued a press release providing initial feedback from its pre-NDA meeting with the U.S. Food and Drug Administration (&#147;FDA&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated October&nbsp;26, 2011</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SIGNATURES </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TITAN PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sunil Bhonsle</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sunil Bhonsle</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: October&nbsp;31, 2011 </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit Index </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated October 26, 2011</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d251175dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g251175img001.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Titan Pharmaceuticals, Inc.</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TITAN PHARMACEUTICALS PROVIDES PROBUPHINE UPDATE AFTER </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Regulatory Path Defined for New Drug Application </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>South San Francisco, CA &#150;
October&nbsp;26, 2011</B> &#150; Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that it met with the U.S. Food and Drug Administration (FDA) for a Pre-New Drug Application (Pre-NDA) meeting regarding Probuphine&#153;, an innovative
subcutaneous implant formulation of the marketed drug buprenorphine. Based upon this meeting, Titan believes that its Phase 3 clinical program completed to date is acceptable to the FDA to support submission of an NDA via the 505(b)(2) pathway and
that no additional clinical efficacy or safety studies are required to support the submission. The company has also received clear guidance from the FDA on the requirements for submitting an NDA for consideration to be designated as a Priority
Review. Titan has received initial comments from the FDA regarding manufacturing and non-clinical information and is in ongoing discussions with the agency to confirm these requirements. The company will confirm the overall regulatory path forward
upon receipt of formal meeting minutes from the FDA in the coming weeks and will provide a further update at that time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are
extremely pleased with this preliminary outcome as we believe it enables Titan to move forward rapidly and efficiently with our ongoing partnership discussions for Probuphine and continue to advance the program&#146;s regulatory process toward an
NDA submission,&#148; said Sunil Bhonsle, president of Titan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Probuphine </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Probuphine is designed to deliver six months of continuous round-the-clock, long-term therapeutic levels of the drug buprenorphine following a single
subcutaneous treatment. Buprenorphine, an approved agent for the treatment of opioid addiction, is currently available mainly in the form of sublingual tablet and film formulations. The safety and effectiveness of treatment with Probuphine has been
demonstrated in several late-stage and Phase 3 studies conducted to date, including a 163-patient placebo-controlled study which demonstrated clinically meaningful and statistically significant treatment with Probuphine over a 24-week period and was
published in the <I>Journal of the American Medical Association (JAMA) </I>and a confirmatory study of 287 patients that showed statistically significant efficacy versus placebo and non-inferiority with a currently marketed sublingual formulation of
buprenorphine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Probuphine was developed using ProNeura&#153;, Titan&#146;s continuous drug delivery system that consists of a small, solid
rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the upper arm in a simple office procedure, and is removed in a similar manner at the end of the
treatment period. The drug substance is released slowly, at continuous levels, through the process of diffusion. This results in a constant rate of release similar to intravenous administration. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Titan Pharmaceuticals </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
information concerning Titan Pharmaceuticals, Inc., please visit the company&#146;s website at www.titanpharm.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The press release may
contain "forward-looking statements" within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the
Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development,
testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization,
the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ
materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Titan Pharmaceuticals, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pure Communications</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sunil Bhonsle, 650-244-4990</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dan Budwick, 973-271-6085</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">dan@purecommunicationsinc.com</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g251175img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g251175img001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`9`!L`P$1``(1`0,1`?_$`-```0`!!`(#`0``````
M```````(!PD*"P4&`0($`P$!``$$`P$!``````````````8%"`D*`0,'`@00
M```%`P("`PD.!`,)``````$"`P0%``8'"`D1$B$3%!65%K;6=SAX&3'1(E*2
M)!<W5Y<86+A902/5.6%""E$R-"4U54?8&A$``0,"`P,%"@D(!@L``````0`"
M`Q$$$@4&(3$305(4!PA187&1P=$B(Q8)L3)"LC-STY05\*%B@I(T51=R)%34
M&!F!9'2T)765-E9V-__:``P#`0`"$0,1`#\`S^*(E$2B)1%JG]6YR?BMU._#
M+Z0^;/\`,'VEW-_C7FLL\(GE!>T$32<HY[EMD=3W_P`DTM_Z[EO^YPJ/?.3X
MY?E![]?'2(.>SQCSKT:H3G)\<OR@]^G2(.>SQCSI4)SD^.7Y0>_3I$'/9XQY
MTJ$YR?'+\H/?ITB#GL\8\Z5"<Y/CE^4'OTZ1!SV>,>=*A.<GQR_*#WZ=(@Y[
M/&/.E0O:NU<KG;7MBXKVN2`LZT861N.ZKIF(ZW[<@(EL=Y*34W+NTF,9&,&J
M8"==V]>+D3(4/=,;IX!0D[`T$O)``&\D[@/#XAO.Q4_-<URW(LLN,ZSB:.VR
MJTA?--+(X-9''&TN>][CL#6M!)/<"S+O_G=LSV<GT>=7%?CLX_2M](O;&_<S
MPS[F]7]!7;_^&^CKN7\Q[3S_`/7?^:=9V?YK4D_`1T'#4?B%<6+DKS/Z--GA
M]+>L+'^8WG?^)/VCQ2_R&_<.AX3CZ-CK^*8-_2\?K<%/W7^JX>+ZY8&7M[-X
M[]PK4%WWM[R=J2+%.GM[-X[]PK4%WWM[R=HB>WLWCOW"M07?>WO)VB)[>S>.
M_<*U!=][>\G:(NOK;WVZ\X55<.-;&4'+A=0ZR[AQ$X\7<+K*F$ZJRZZMEG56
M65.83&.81,8PB(B(C7R6,)J6MKX`JQ'J+4<,;88<RS%D+&@-:VZG:UH`H`UH
MD```V````;`OS]MQNK_G2R5WDQQY$TX<?-;X@OOVFU1_%,S^]W'VJ>VXW5_S
MI9*[R8X\B:<./FM\03VFU1_%,S^]W'VJ>VXW5_SI9*[R8X\B:<./FM\03VFU
M1_%,S^]W'VJ>VXW5_P`Z62N\F./(FG#CYK?$$]IM4?Q3,_O=Q]JGMN-U?\Z6
M2N\F./(FG#CYK?$$]IM4?Q3,_O=Q]JIO[9N[?N.YEW%M"N(\H:J[XO3&V3=6
M>!+%OZSYF`QXK$739]SY)MZ)N&WI--*S453Q\Q%N56ZP%.0_5J#RF*;@8..'
M'S6^(+D:GU0#49IF=?\`:[C[1<SG)-)#-F8T44TT$4<K9%2211(1)%%).\)D
MB:2228%3223(``4I0`"@'`.BO.`0"\G<)9/GN6V1H1SGZ(R9[R2\Y5:$DFI)
MX$=22=I)Y25EP_Z?/:]\"(2-UX9XMODO&Z(]4NG.U)ID4%K7M.004;/LKO&K
MD#*H3MW-53MX7F(F9O$F4<@*@/T11DN29?NS"<>D1ZL'D!^41W7<E=H;W*E8
M?_>(=J?\=OI>H/0-S7)K60?C$\;C2>=A#FV#2-ABMW`/N=K@^?#$<)@D#\J^
MI*L3:T$]$2B)1$HB417P-*.AW0Y=&BG%^IC4R]U:RMXY6SCGW&$5!8%OG#=G
MVO!PF%(/"\FF_D29#Q3?LL_EIQQE@X"*3A)%,C0/@<3<1IF8YD,NP5C=)CKN
M(%*>$A78]F#LH9WVG&9V_*,ZM<H&2NM`[C6\EP9>EBX(PX)8L`9T<UKBQ8Q2
ME#6H[[2=L^Q;8SR29;CS%J4Q2"NZSEI:2(90_P#N(I\VFWF674_RID`QS#[@
M#5/9J$R.#([69SSR`L)^%7)ZC]V5F.CLFFU%JWK"R#+,AMQ62XNK22&%G>+Y
M+P#$>1HJYVYH)7?X;;VVUKBB%K@@L,[N<M`-TE'"\ZQN;"J\,DW2`#*.5),N
MD[L1&Q4QYQ4$X)\@";CR@(A^EV:7C&XW6-QA\,9_,'$_F7AF5]F'J7SG-OP2
MPZZ='F_Q%HQV=U#$YP-*,GFGC@?4_%PR$.&UM1M72PT@;10@`A#[DH@(`("&
M;M+@@(#[@@(:;1`0'_;7XQJ5AW6\O[3/.KBX_=4ZPFC;-#K7*GPO:'-<W+YB
MUS2*AS2+L@@C:""01M"\_@_VB_\`LVY-]]NEW_UMKGVD;_9Y?VF>=??^5+K3
M_P`SRO\`Z=/_`'M5NTT8VVL]+>HC!NI2R;.W![@O+`>5[#R_:L'=>:=-RML2
M]P8^N2/N>)C;@3A]/<7*J0SU[&D3<@V<H+BB8P$4(;@8'M(W^SR_M,\ZY'NI
M=9UVZSRRG_+Y_P"]*[GM$[=0[AVJ.]M1^4[6<M=+-CY*G+PFXB3!-9ODB]9>
M:<W-"XK*N=(B4E"1A'J+BXE$TQ(=GR-`ZL[T%$J9E5ATZ=SY1_5&R.)_2<7%
MP9WPVHQTV'XO="ND[8?:0_PZ=5=CU:Z4NV/ZU;_+8[>.1E0;.V9&(9;ZE262
M/+7,M`3425E](0%K\]QHT:L&K9BQ;-V3)DW1:,V;1%-NU:-6Z946[9LW1*1)
M!N@D0"D(4`*4H````!4XW;!N6O\`RRRW$KIYW.?.]Q<YSB2YSB:ESB:DDDU)
M.TG:5]%%UK2H>QKW9?VX-9OW`9!_HU$7`Q6TINA3LI<\+#;?FKF4E[*E6<%=
MT:QP;?;E[;4S(0$/=3&+FFZ4292/?N[:N!B_324`IS-':*@!RJ%$2+GO8U[L
MO[<&LW[@,@_T:B)[&O=E_;@UF_<!D'^C416X9"/?1+]]%2C-Q'R<6]=1TE'O
M$C(.V,@Q74:O63I`X`=%RU<I&34((`)3E$!Z0HBR'\%&(7::TA&4.":9-7.O
M4ZBAN@J:9;0T<&.<P_P*0H"(_P"`5&M0[X*;ZN\BS%>Z?=&RWUY),X,A:_*"
MYQW-:&9D7./>`!)[P52-LO&-N:@<N(Y1OU!*1B4YD6UC1$@!5X^#A&[HB23M
M!N8G4C*2B?\`/67Y15,*@)@/(0H!6,OLV6D(8`.*1Z1Y2>YX!N`5@W:B[06H
M^T'UF7N=W=Q,-$6=S)%E5GB/!@MF.+&38!1KKBY`,TLSFF3TQ$'"-C6K94Z0
M8S'MH8IBH>VF\3$&303%QU96S8ZR1$4RE`3?!$Q43%$!`1]VOVJVY897^H@P
MGB'%6KRT,AXCBX6WF6:XB01OR$MYJV91!\F0S9655N=LR9D2;M'-T0R*W=#D
M*!5WK8'`_P`U98YXYGEDP,Z=&`'U`?WZ[`?"#05Y0=NX++3[M3M":B;JM_9_
MU/<R76G;FSFN,JXA+G6LUN.+/:L<:NZ/-#CECC^+%)&[!A;(0+!]1M9IE+C1
M%HZR9KFU"6=@?&J"K3NJN$I?%Y*,U'D3CRPF"Z(7#=\N4%&Z:G8T52I,VQE4
MA?R"R#8IRBKS%[;>WDNYVVT.QYVD\UO*3\`'*>\"O'NO3KGTQU#]75[K[4S@
M\Q-P6ML'!LEW=/!X-O'L)&(@ND>&N$437RD$,H=F'I[P%C/3!ARQ,&8A@4K?
ML3'\*C$Q;?@D=_(N1$R\I<$X[221[I7%<,DJJ\?.3%`5W*QS<"@(%">6]O%:
MPMMX12-HH/.3RD[R>4K6&ZQ.L#4_6EK._P!=ZPN#<9]F$YD>=N%C=T<,323@
MAA8&QQ,J<+&@5)J36>NY0I*(E$4,=-WI$[A7K&8I_1?IAHBF=1$HBT.F;/KH
MS!YU<B^.,S1%?9P@CVC:3TD-N8"=IU9Z^F_.(<0)U]F:.TN<0Z.($Y^(U&]0
M&CH#W"[R+,'[JBVZ;EW6#9!P89AE<>([F\2+,V8CWA6I\"Z;MNZ@4,/O#V3/
M+=S9:VI->%?-U3=09-U'N!;',!5!*!>NZHJB8B'`Q1`>(@/&I#'(V5@D9M:1
M58FM4Z9S;1>I<PTAGT3H<YRN\FM9F.!!$D+W1DT-#1U,33RM((V%955C[F3:
MV;330)<2)>K:\WPG2A#&*4@?"X%$`*?HZ#!Q$1_C_$>RH.]4%8\.X!J\<ZL]
M1-@04>^/)LK`<S%Z3KQ%83H-`+%O82,;*J`"A14?OI7@"8B`G(F<W'X(U2<Z
ME:RQ<P_&>0`/]-3\"OC]W?HG-=5=IO*L[LV2#*M/VUU?7,C:AK0Z"2U@C<:$
M$S33M`C)!>QDC@?0*HU9MG73D*[+;L2R(&2NB\;PFXVW+8MV';G=R<U.2[I-
ME'1S)N3I.NY<K%*''@4H<3&$"@(A##6H:T$O<0`!O).X?EN%2=@*V&,[SK*M
M.91<Y_GMQ%:Y-9P/FGFD.%D<4;2Y[W'D#6@GN\@VK8^;56W/:6WOI]8V^[0C
MY?/&0FT=/YOO5`$UP7FRI**,;*@'7`3DM&RTG1FZ'`W!Z[%=X8"]>5)*;99E
M[;"'TMMP_:\]_N#N-'(/"=Y*UJNUAVD<X[1/6')F,3I(=`Y<Y\666QJ*15`=
M<RMW=(N2T/=L]7'PX03PR]]T&JDK64HB41*(H8Z;O2)W"O6,Q1^B_3#1%,ZB
M)1%H=,V?71F#SJY%\<9FB*^]@G^TWI`];K7IXI:.*C6H=\/ZWD68KW3WT.N_
MK,H^;F*B[D/"L?=\N%W6[-N[*O@B":*DTP1(X83!&X`5L6>CN9$SE1!,.0BZ
M:A%BDX%'G`I0"GV69S68X=,4/<[G@/D5V/:8[$?5]VA[XZMMKF3(NL?@ACKR
M*-LL-T&`"/IL%6&1[&@1MGCD9*(P&O$K6,#>IM\?:AW`#'2.7(!C%\AD3/(M
MC-O9$Z(&`H=6S=F9-$E#I=(\53`!NCI#IJJNS^+#Z$;B_OD`>7X%8YE'NI^L
M&7-.'G^K<DAR0./K+>WNYIRW%LI%*((PXMJ=LQ#7;/2&U5CL6PH3'\4LQC#N
M7SY\MVR=N"3,168G7P`(`Y?KE*4I4D"")442`"2).@H<1,8U`N[N6ZD,TQH`
M-@Y`/RWE94.HSJ'T#V?=&C2&AH7%TCQ)=WDV$W5[,*@23O:``U@);#"P".)M
M<(+G/>_-"V$=N62Q%=V,=6V<+=(C>.6<9Y3FL*6E.Q1.W63:,6_Q>P89+/VK
MYPPN2]XR[GR+$G5E%"$6!7G,+WE1KF29?0"_G'K"/0!^2T_*(YSOS#9RE8JO
M>&]J=VJLV?U$Z`N@=,6,M<VGC=LNKJ,^C9-(V&"U<,4VTB2Y`80.CU?EK5(U
MBL2B)1$HB410QTW>D3N%>L9BC]%^F&B*9U$2B+0Z9L^NC,'G5R+XXS-$5][!
M/]IO2!ZW6O3Q2T<5&M0[X?UO(LQ7NGOH==_691\W,5TJHZLPJ417YMD':\6U
MGY9)G+,,&L.F7#LZV5=L7S50&>7K_8BB^8V(@<QT07MF&YTG<ZH7K"J)BDQX
M?.5#HU'*[#I\W$D_=(W;?TW#Y/\`1&PNIO/H\X*P'MT=JAG4KI$Z$T;.W^9^
M<P.#7,<,67VCJM=='8:32>E':@T(=CGKZIK7YQLZ@BVSUAYLV12;MV^*LVH(
M(()D21012G\&)I(HI)@4B:29"@4I2@```<`J;;EKXR2/E>99272.)))-22=I
M))VDD[23O5;Z+X2B)1$HB410QTW>D3N%>L9BC]%^F&B*9U$2B+0Z9L^NC,'G
M5R+XXS-$5][!/]IO2!ZW6O3Q2T<5&M0[X?UO(LQ7NGOH==_691\W,5TJHZLP
MJF5H/T6Y(UX:B+3P;8";B.C7*A)O(]\]A.\C<=X^8N4"3MSOB<R2*ST2JE;1
MK4ZB7;I%9%'G(4QU"=MM;R7EP+:(T<15QYK>[X3N:#O/>!7BO7[UW::Z@NKB
M\UUJ`MDNF@Q6=KB#7WEVX'A0-WD-V%\T@:[A0M>_"X@-=LOL%80QMIOQ+8V$
ML1V^A;5@8]@VT%!1R?*HY6*EQ4>RTL[`A%).>FWZBKM\[4#K'3M910W2:IY!
M!%;0M@A%(VB@_+E)Y3RE:Q.O==:EZRM7W^N-7W#KK4&8SNEE>=@%=C8XVU(9
M%$P-CBC&QD;6M&P+C[D]('$GFOSCXPX-KN405:J(E$2B)1$HBACIN](G<*]8
MS%'Z+],-$4SJ(E$6ATS9]=&8/.KD7QQF:(K[V"?[3>D#UNM>GBEHXJ-:AWP_
MK>19BO=/?0Z[^LRCYN8KY["L2\,H7K:N.<?V_)77>][3L;;-K6Y$-S.9&8FY
M9R1HQ9-DB^X)U5.)SF$$TDP,<XE(4Q@CFTN#&"LCB``-Y)W#RGN`$G8"LMNH
M=09-I3([O4FH;B*TR.Q@?-/-(<+(XXVESG$]X#8!4DT`!)`6R$VM-O&T]O;3
MM&V<HG&3&:[Z3C[ESA>[,#+$D[G[,/9K5@W:Q$UQL^RDG!VC$.5+M2HK/#II
MJ.3$+-\LL&V$&$[9W;7N[I[@[S1L'C.TE:TW:L[1F;]HGK'ESEIEAT18%\.6
M6SMA9!BVSRM!(Z1<D!\FUV!N"$.<V(.-S&JBK8516Y/2!Q)YK\X^,.#:(JU4
M1*(E$2B)1%#'3=Z1.X5ZQF*/T7Z8:(IG41*(M#IFSZZ,P>=7(OCC,T17WL%#
MPVFM((CT`&KK7H(B/\`\$='%1G49#1"YQHT8_@"S%>Z>^AUW]9E'S<Q69WL`
M[7H87LQCK8SI;AD<N9&A3$PM;$RS.1UCG&\PW**EXN6KH"F:W?D-HH'4?RP5
M8P@@`'YG[A)+LR7+RP=.G'K7#T`?DM/*?TG?F&SNU\Y]X3VI_;;.Y.I#0=S7
M2&6S_P#$IXW>C>7D9V6[7-^-;VCAZ>W#+<UJVEO&]^3E4B6+M*(J*W)Z0.)/
M-?G'QAP;1%6JB)1$HB41*(H;6G9F:L6YGU0WA#6!;%[VSG#)UC7_`&V\)D4+
M=DHQE;N`,/XGD(R:BGUINR)/>[V.W;A,Z#E=-1HNB(\BG.0"*JWAMG7["X+[
MX8[R.HB>&V=?L+@OOACO(ZB+5>YLVG](T=F?+S"Y]RU_"W*RRED)K<4,UT2Y
M"F6L1/-[NF$IB,:RZ67VB4JW82)5$B.2I)E7*0#@4H&X!1':@RYCW,/%Q-<6
MGU;M[20:&FT5&P\JO<R'W>_:3U)D=GJ'*[;)#EE_:17$)=F`:XQ3QMDC+F\$
MX787"HJ:'94K(RVCMK''U_X-TTQ=H7%(:ML!Z8-0VI'*ET2MV6!,Z;X+)-]9
M1A<`H6?8T1'7.^R`-V6O9KS%;EW<:I%T4E3.&C#D.51T*?R.BYZ^.X9CZ-"]
MU0YI;B<*4&T;0T[Z?*&'G!5Z+..LKL-Z,U5U;YE)81=:.KV6'!?9W3;@Y?90
MMO67$\A#&&*YFX[&6@I4#BSU:8XP_,.)>6<DB$33P1`)IIE*1-,F7XTA"$(`
M%*0A2V:!2E*4.``'0`5758,YSG.+G$EQ-23O)7MX;9U^PN"^^&.\CJ+A/#;.
MOV%P7WPQWD=1%\$&QRE<V6;3O"[K#A+*@K3L7(4%SMKZ2NE_)2EX3..';)-%
MDVMV+2;M6S6T')E53K<0,=,I2&YC&(12"HB41*(E$2B)1$HB41:WW&FB'(6O
MG<YSKA2S>U1%N$U%9FN#*E^D9F=,L?X]9Y5N$DO,G`0!NO-ON<&D2T.8@.Y!
M5,IC$1*LJG`(;:2]OGVT1IZV0N/-;C=M\)W-KO->X5LJZEZ]-.]G[LN9#K;.
ML$V9G3F716-IBPNN[MUC$8XQRB-M.)/(`>'$UQ`<\L8[8:88P[CO3]BVQ\-8
MHMUM:V/\>P#.W;;AVPB<R;1H415>/W1^*\C+RCHZCEZ[6$R[MTLHLH8QSF$9
MU##';Q-AA%(VB@"UT]:ZSU'UAZKOM::MN776H<QN'332'95SMS6-&QD;&T9'
M&VC8XVM8T!K0%4ZNU19*(E$2B)1$HB41*(E$2B)1$HBL^[0OX8_!/5-]#?-]
M-/XL,Y_B;[L]1X4^%_TGWIX)]1U?_C[P9Y>XO5_RNL[7UGSSM547)>B\.;@5
MX_2).)6F+%C=3=\FE,'Z._TJJ\;MA?S0_%M*>V?_`&1[)Y9^"<.O`Z/T*VZ1
B7_6^/7I-?2P\'#ZGA*\%5:5G*41*(E$2B)1$HB41*(O_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
